What are BPC-157 and TB-500?
BPC-157 — "Body Protection Compound-157" — is a synthetic pentadecapeptide (15 amino acids) that corresponds to a fragment of a protein first identified in human gastric juice. It is unusually stable in solution, which is part of why it became popular in research settings.
TB-500 is a synthetic fragment of Thymosin β-4, a naturally occurring protein that regulates actin, the cytoskeletal protein cells use to move. The fragment is marketed as reproducing much of the parent protein's activity. It is worth being precise here: "TB-500" and full-length "thymosin beta-4" are often used interchangeably in vendor literature, but they are related, not identical — a distinction that matters when you look at the evidence.
Critically, neither is an approved medicine. Both are sold as research chemicals labeled "not for human consumption," and both currently sit in the FDA's Category 2 of bulk drug substances — the tier flagged for significant safety questions, which bars compounding pharmacies from preparing them for people.
What does the human evidence actually show?
This is where honesty matters most, because the gap between marketing and evidence is wide. The overwhelming majority of the "healing" and "recovery" claims attached to both peptides come from animal studies and laboratory experiments — not from controlled trials in people.
For BPC-157, a 2025 narrative review in Current Reviews in Musculoskeletal Medicine put it bluntly: only about three pilot studies have examined BPC-157 in humans, "human data are extremely limited," and there is no completed published randomized controlled trial for any musculoskeletal indication. The same review noted the peptide's popularity rests on "wide availability through non-regulated sources" rather than clinical proof, and recommended it still "be considered investigational."
For TB-500 the picture is more nuanced, and worth getting right. The synthetic "TB-500" fragment that vendors sell has no published human randomized controlled trial at all. The only controlled human data is for the full-length parent protein, thymosin β-4 — and even that is in narrow indications unrelated to the systemic "recovery" marketing. A small Phase 2 trial of thymosin β-4 eye drops (RGN-259) in severe dry eye, for example, found the drops "safe and well tolerated" and reported some symptom and corneal-staining improvements, but that nine-patient ocular study tells you essentially nothing about injecting a fragment for tendon or muscle recovery. In other words, the human evidence that does exist is for a different molecule, a different formulation, and a different problem.
The practical takeaway: effects seen in rodents — and a handful of small, narrow human studies of a related protein — do not reliably translate into a proven recovery benefit in people. For the way these compounds are actually marketed and used, any benefit remains unproven for both.
How do the proposed mechanisms differ?
In the preclinical literature, the two are described as working through different pathways. BPC-157's narrative centers on angiogenesis — promoting new blood-vessel formation (via VEGF signaling in animal models) — alongside effects on tendon, ligament, gut, and skin tissue. Notably, in isolated cell cultures it showed no direct angiogenic effect; the effect appeared only in the in-vivo healing context.
TB-500's proposed mechanism centers on actin. The parent protein thymosin β-4 is described in the literature as the major actin-sequestering molecule in cells; by binding G-actin (monomeric actin), it is thought to support the rapid cytoskeletal remodeling cells need to migrate — which in turn is linked to dermal and corneal wound healing and to angiogenesis. So one narrative is framed around blood-vessel and tissue repair, the other around cell movement. Both descriptions, again, rest largely on animal and in-vitro work, and the marketed TB-500 fragment is assumed — not demonstrated in humans — to reproduce the parent protein's activity.
What about route, stability, and how long it lasts?
One reason BPC-157 became a research curiosity is stability. Because the sequence was derived from a protein native to gastric juice, reviews describe synthetic BPC-157 as unusually stable in human gastric juice — unlike most peptides, which are rapidly degraded there. That is the basis for the oral-dosing claims you see online. It is important to read that claim precisely: "survives the stomach in a test tube" is a chemistry observation, not evidence that swallowing it produces a measurable clinical effect in a person.
Stability in the gut is also not the same as staying in the bloodstream. A 2022 preclinical pharmacokinetic study in rats and dogs found that injected BPC-157 is cleared very quickly — an elimination half-life under roughly 30 minutes (about 15 minutes in rats, around 5 minutes in dogs). That rapid clearance is why dosing schedules in the hobbyist literature are split through the day, but it is animal data: there is no published human pharmacokinetic profile for BPC-157, and none for the TB-500 fragment either. So how either compound behaves in the human body — absorption, distribution, an effective dose, or a safe one — is genuinely unknown.
What are the documented safety risks?
Honest safety reporting here means separating two different things: what the few human studies observed, and what the product itself introduces. In the small BPC-157 pilot studies, no serious adverse events were reported, and thymosin β-4 in its trialed (mostly topical/ophthalmic) forms was described as safe and well tolerated. But "no adverse events in a handful of tiny, short studies" is a long way from an established safety profile — there is no long-term human safety data for either compound, no data on repeated injection over months, and the theoretical concern most often raised for any pro-angiogenic or pro-migratory agent (could it feed abnormal tissue or tumor growth?) has simply not been resolved in people.
The second risk is the product, not just the molecule. Because both are sold research-use-only and labeled "not for human consumption," the material that reaches consumers is not manufactured, tested, or released as a medicine. There is no USP monograph and no FDA-approved source, so what is actually in a given vial — its identity, peptide purity, dose accuracy, endotoxin level, and sterility for injection — is not guaranteed. The FDA itself catalogs both peptides among bulk substances it has flagged as potentially presenting "significant safety risks." For an injectable used outside any regulated supply chain, contamination and mislabeling are real, documented categories of risk independent of whatever the peptide may or may not do.
What is the regulatory status — and is it changing?
Neither BPC-157 nor TB-500 is approved by the FDA, neither has a USP monograph, and neither is a component of any FDA-approved drug. Their status under the compounding rules has been a moving target. The FDA placed BPC-157 in "Category 2" of bulk drug substances — substances that "may present significant safety risks," which compounding pharmacies were not permitted to use — in 2023. In April 2026 the FDA removed BPC-157 and TB-500 from that Category 2 list, but removal did not make them approved; it left them in a regulatory gray zone, neither cleared for compounding nor formally barred. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review these peptides (July 23-24, 2026) to weigh whether any belong on the 503A bulks list at all.
For athletes the line is far simpler and has not moved: TB-500 (thymosin β-4) is explicitly named on the World Anti-Doping Agency Prohibited List under Section S2.3, banned at all times, in and out of competition; BPC-157 is also barred in tested sport as a non-approved substance (category S0). The bottom line for a reader today: regardless of where the compounding debate lands, neither peptide is an approved, quality-assured human medicine right now, and the evidence underneath the marketing has not changed with the paperwork.
A note on tracking experimental protocols
PeptidePanel does not sell, source, supply, endorse, or prescribe any compound, and nothing here is medical advice. Both compounds discussed on this page are unapproved and of unverified safety and efficacy in humans.
If you are working with a qualified clinician who is monitoring an experimental protocol, the monitoring discipline is what reduces risk: tracking doses, watching the relevant bloodwork, and documenting any adverse effects. PeptidePanel is a neutral tool for that record-keeping — but the decision to use any investigational compound is one to make only with a licensed physician who understands the risks.